Genexine, Inc.

Genexine, Inc.

Genexine, Inc.

Overview
Date Founded

1999

Headquarters

4/F, Korea Bio Park Bldg. B,700 Daewangpangyo-ro,Bundang-gu,Seongnam-si, Gyeonggi 13488

Type of Company

Public

Employees (Worldwide)

156

Industries

Biotechnology

Company Description

Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. It operates through the following business divisions: Novel drug development and Cell culture media manufacturing. The company was founded by Young Chul Sung on June 8, 1999 and is headquartered in Seongnam, South Korea.

Executives & Employees

Founder

President

Chief Financial Officer & Managing Director

Executive Vice President & Chief Operating Officer

Executive Vice President & Chief Strategy Officer

Executive Vice President & Chief Medical Officer

Chief Executive Officer, R&D

Vice President & Head, Research Institute

Executive Vice President & Head, Bio Research Institute

Senior Vice President & Head of Clinical Division

Board of Directors

Founder at Genexine, Inc.

Chairman & Chief Executive Officer at Handok, Inc.

Vice President & Head, Research Institute at Genexine, Inc.

Independent Director at Genexine, Inc.

Member, Board of Directors at Genexine, Inc.

Executive Vice President, Deputy Director of Bio Research Institute at Genexine, Inc.

Co-Founder at InterVest Co., Ltd.

Executive Vice President & Head, Bio Research Institute at Genexine, Inc.

Paths to Genexine, Inc.
Potential Connections via
Relationship Science
You
Genexine, Inc.
Owners & Shareholders
Details Hidden

NH-CA is an active, team-based manager which believes that portfolio allocation must be based on careful assessment of market risk and seeks to deliver a consistent return for the risks assumed.The firm's equity investment process begins with the investment committee allocating sectors, picking stocks and developing the risk allocation model and model portfolio. Portfolio managers then construct portfolios based on client needs and perform risk monitoring of the actual portfolios. Finally, the investment/risk management team evaluates portfolio and benchmark performance.The portfolio managers use the firm's proprietary portfolio risk monitoring panel to identify potential risk sources, conduct simulations, show changes in volatility, performance and portfolio exposure as managers reshuffle portfolio risk through asset allocation revision and stock picking.Fixed-income investments follow a combined top-down and bottom-up approach which begins as the investment committee performs strategic analysis using macroeconomic data. They then work with credit analysts and fund managers to conduct yield and credit reviews. Researchers and fund managers construct the risk-adjusted model portfolios based on clients' guidelines and risk assessment, and then the fund managers perform relative value analysis to construct the final portfolio.

Details Hidden

NH-CA is an active, team-based manager which believes that portfolio allocation must be based on careful assessment of market risk and seeks to deliver a consistent return for the risks assumed.The firm's equity investment process begins with the investment committee allocating sectors, picking stocks and developing the risk allocation model and model portfolio. Portfolio managers then construct portfolios based on client needs and perform risk monitoring of the actual portfolios. Finally, the investment/risk management team evaluates portfolio and benchmark performance.The portfolio managers use the firm's proprietary portfolio risk monitoring panel to identify potential risk sources, conduct simulations, show changes in volatility, performance and portfolio exposure as managers reshuffle portfolio risk through asset allocation revision and stock picking.Fixed-income investments follow a combined top-down and bottom-up approach which begins as the investment committee performs strategic analysis using macroeconomic data. They then work with credit analysts and fund managers to conduct yield and credit reviews. Researchers and fund managers construct the risk-adjusted model portfolios based on clients' guidelines and risk assessment, and then the fund managers perform relative value analysis to construct the final portfolio.

Recent Transactions
Details Hidden

Genexine, Inc. issued Ordinary Shares

Transaction Advisors
Underwriter

Advised onGenexine, Inc. issued Ordinary Shares

Clients

Shanghai Fosun Pharmaceutical Group Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products and medical equipment, import and export of medical equipment, healthcare services, and the provision of related and other consultingservices and investment management. It operates through the following business segment: Pharmaceutical Manufacturing and R&D; Healthcare Service; Medical Devices and Medical Diagnosis; Pharmaceutical Distribution and Retail; and Other Business Operations. The Pharmaceutical Manufacturing and R&D segment involves in the production, sale, and research of medicine. The Healthcare Service segment provides healthcare service and hospital management. The Medical Devices and Medical Diagnosis segment focuses on the production and sale of medical equipment and diagnostic products. The Pharmaceutical Distribution and Retail segment issue retail and wholesale of medicine. The Other Business Operations segment comprises businesses that is different from the role of other segments. The company was founded on January 14, 1994 and is headquartered in Shanghai, China.

Government of South Korea provides news about Korea, Korean government policy, information on Korean history, Korean culture, and traveling in South Korea. It is composed of executive, legislative, and judiciary branch, independent organizations, and local governments.

Dong-A Socio Holdings Co., Ltd. engages in the manufacture of pharmaceutical preparations and products. It operates through the following divisions: Holding Company, Pharmaceuticals, Logistics, Packaging, and Others. The Pharmaceuticals division manufactures and sales pharmaceutical products such as prescription medicine and over-the-counter drug. The Logistics division offers cargo, courier, forwarding vehicle transportation arrangement, transport and lease of warehousing. The Packaging division manufactures and sales glass and glass products. The Others division is engaged in information technology solution, production and sales of agricultural products, and real estate development businesses. The company was founded on August 9, 1949 and is headquartered in Seoul, South Korea.

Key Stats and Financials As of 2018
Market Capitalization
$1.18T
Total Enterprise Value
$1.34T
Earnings Per Share
$-1,675.26
Revenue
$12.9B
Net Profit
$-34.1B
EBITDA
$-40.5B
EBITDAMargin
-314.26%
Total Debt
$34.6B
Total Equity
$321B
Enterprise Value Sales
104.1x
TEVNet Income
-39.36x
Debt TEV
0.03x
Three Year Compounded Annual Growth Rate Of Revenue
-26.56%
Five Year Compounded Annual Growth Rate Of Revenue
17.49%
Suppliers
Binex Co., Ltd. Biotechnology | Busan, BU

BINEX Co., Ltd. engages in the manufacture and sale of pharmaceuticals. It operates through the following business divisions: Bio, Pharmaceutical Manufacruing and Sales, and others. The bio division provides bio pharmaceutical consignment production and bio analysis services. The pharmaceutical manufacturing and sales division offers medicines for digesting, antiinflammatory analagesic drug, probiotics, collyrium, antibiotics, urinary system disease, circulation disease, external ointment, antitussive expectorants, and others. The others division provides processing services. The company was founded on December 17, 1957 and is headquartered in Busan, South Korea.

Competitors
Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Teva Pharmaceutical Industries Ltd. Pharmaceuticals - Petach Tikva, HM

Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 46,000 employees worldwide. Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence

Novartis AG Pharmaceuticals - Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Genexine, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Genexine, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Genexine, Inc..